Key to biosim­i­lar com­pe­ti­tion will come from in­ter­change­abil­i­ty, FDA of­fi­cials say

With the growth in bi­o­log­ics spend­ing, the biosim­i­lar mar­ket is go­ing to have to find new ways to keep up.

One av­enue may open up with new in­ter­change­able biosim­i­lars that can be sub­sti­tut­ed with­out a doc­tor’s note, and which could help bring costs down for some prici­er, pa­tient-ad­min­is­tered ther­a­pies. FDA of­fi­cials dis­cussed key flex­i­bil­i­ties that they can make around the de­vel­op­ment of in­ter­change­able biosim­i­lars at an As­so­ci­a­tion for Ac­ces­si­ble Med­i­cines’ in­dus­try con­fer­ence yes­ter­day in Bethes­da, Md.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER